

## REVIEW ARTICLE

# Role of Computational Biology in Diagnosing the probable causes of Nerve Damage

Jahnavi<sup>1</sup>, Prekshi Garg<sup>2</sup>, Prachi Srivastava<sup>3</sup>**HOW TO CITE THIS ARTICLE:**

Jahnavi, Prekshi Garg, Prachi Srivastava. Role of Computational Biology in Diagnosing the probable causes of Nerve Damage. J Surg. Nurs. 2025; 14(2): 218-228.

**ABSTRACT**

Neurodegenerative diseases and nerve injury are among the most formidable medical conditions today due to their complicated molecular basis, multiclonal clinical presentations, and restricted therapeutic options. Computational biology has revolutionized the tools available for studying these diseases by combining information from multiple high-throughput platforms, such as genomics, transcriptomics, epigenomics, proteomics, and metabolomics. Using computational pipelines, scientists have discovered dysregulated pathways, miRNA biomarkers, and epigenetic changes that underlie neuropathic pain and chronic nerve damage. For instance, bioinformatic approaches have identified the regulatory function of certain miRNAs in ion channel function, neuroinflammation, and neuronal excitability, while epigenetic analysis has accounted for the chronicity of pain by way of histone-based gene silencing. Multi-omics integration in neurodegeneration has found there are common molecular signatures across Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis with implications for shared pathways of stress response, apoptosis, and synaptic dysfunction. Computational modeling, such as machine learning and network biology, also facilitates the discovery of predictive biomarkers and regulatory hubs as potential therapeutic targets. Notably, these approaches are also useful in uncommon neuropathies, when patient groups are small and for direct experimentation, usually restricted. In the future, the intersection of AI-enabled analytics, single-cell and spatial omics, and systems-level network modeling will allow for improved precision diagnostics and inform personalized therapy approaches. So, computational biology not only enhances our mechanistic insight into nerve injury but also has the transformative power of personalized medicine in neuropathies and neurodegenerative diseases.

**AUTHOR'S AFFILIATION:**

<sup>1</sup>Student, Department of Biotechnology, Amity Institute of Biotechnology, Lucknow, Uttar Pradesh, India.

<sup>2</sup>Founder and Director, Department of BioinfoCore Solutions, India.

<sup>3</sup>Associate Professor, Department of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India.

**CORRESPONDING AUTHOR:**

Prachi Srivastava, Associate Professor, Department of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India.

E-mail: psrivastava@amity.edu

➤ Received: 19-11-2025 ➤ Accepted: 20-12-2025



Creative Commons non-commercial CC BY-NC: This article is distributed under the terms of the creative commons attribution non-commercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Red Flower Publication and Open Access pages (<https://rfppl.co.in>)


## KEYWORDS

- Computational Biology • Nerve Damage • Neuropathic Pain • Neurodegeneration
- Multi-Omics • miRNA Biomarkers • Personalized Medicine • Network Biology
- Machine Learning

## INTRODUCTION

Nerve damage, medically termed as peripheral or central neuropathy depending on the location, refers to injury or dysfunction of the nerves that carry signals between the brain, spinal cord, and the rest of the body. Nerves play a crucial role in transmitting electrical and chemical messages that regulate sensations, muscle movement, and autonomic functions. When these fragile structures are injured, the outcome can be anywhere from some numbness and tingling to extreme pain<sup>8</sup>, muscle weakness, or even loss of function in involved areas. Unlike most other tissues, adult neurons have very little ability to regenerate, making nerve injury notoriously difficult to treat and often permanent. The etiology of nerve injury is extremely varied. Traumatic causes like accidents, surgical mishaps, or bone fractures causing compression can physically crush or cut through nerves. Metabolic and systemic diseases like diabetes mellitus, the most prevalent cause, result in diabetic neuropathy<sup>2</sup> due to longstanding high blood sugar levels causing damage to the small blood vessels supplying nerves. Autoimmune diseases like multiple sclerosis, Guillain-Barré syndrome<sup>3</sup>, and lupus can lead the immune system to incorrectly attack nerve tissue. Infections (like herpes zoster, HIV, or Lyme disease), toxin exposure (alcohol, chemotherapy agents, heavy metals), and genetic disease (e.g., Charcot-Marie-Tooth disease) are also major factors. Degeneration with aging and neurodegenerative conditions like Alzheimer's or Parkinson's also make a person susceptible to nerve damage. Nerve injury can be broadly classified into different types according to the etiology and clinical presentation. Peripheral neuropathy consists of peripheral nerves<sup>1</sup> to the brain and spinal cord and is characterized by loss of feeling, burning sensation, or extremity weakness. Autonomic neuropathy


consists of nerves innervating involuntary function and results in arrhythmias, fluctuating blood pressure, or gastrointestinal malfunction. Cranial neuropathies consist of damage to nerves directly emanating from the brain, and their functions are affected, such as vision or facial movement. Central nervous system nerve injury, such as spinal cord damage or brain-related neuropathies, causes greater functional impairment based on the absence of regenerative capacity of central neurons. These types mostly overlap, so clinical identification becomes complicated. Nerve damage is still challenging to diagnose with its multifactorial etiology, overlapping symptoms, and frequently slow evolution of the disease. Early signs of numbness or tingling are replicated by other musculoskeletal conditions, whereas pain and weakness are inappropriately blamed on arthritis, vascular disease, or psychiatric illness. Furthermore, even standard imaging techniques such as MRI or CT scans are incapable of making a diagnosis of micro-level nerve dysfunction. Although nerve conduction studies, electromyography, and more advanced molecular diagnostic tests provide greater specificity, they are invasive, expensive, and not widely accessible. Biomarker identification and computational biology approaches are increasingly being requested to increase the precision of diagnosis, but one all-purpose early and consistent detection criterion does not exist. The complexity of nerve damage lies not only in its varied etiologies and presentations but also in its subtle course until extreme functional loss follows. This complexity reiterates the necessity of holistic strategies that integrate clinical observation<sup>4</sup>, molecular typing, and computer biology to understand the mechanistic pathways of nerve damage and to construct more effective diagnostic and therapeutic modalities.



**Figure 1:** The Role of Nutraceuticals in Neuroprotection through which nutraceuticals mitigate neuroinflammation as well as neuronal damage and thus, may slow the advancement of neurodegenerative disorders

Computational biology, also known as bioinformatics, is an interdisciplinary science that applies mathematical models, algorithms, and computer-based tools to analyze biological data. Due to the fast pace of technological advances in next-generation sequencing (NGS), proteomics, and metabolomics, large amounts of molecular data can now be derived from patients with neurological disorders, such as nerve injury. But the size and complexity of this data make it all but impossible to analyze without computational methods. Bioinformatics enables researchers to sort, compare, and analyze these datasets to uncover hidden biological patterns, signal pathways, and potential biomarkers that may uncover why nerve injury occurs and how nerve injury occurs. With nerve damage, computational biology acts as an intermediary between unprocessed biological information and clinical insight. For example, transcriptomics via RNA-Seq can separate differentially expressed genes (DEGs) in damaged nerve tissues from controls. These DEGs could be important candidates that are implicated in inflammation, axonal degeneration<sup>5</sup>, or dysfunctional synaptic transmission. Using computational pipelines such as quality control, normalization, and

statistical testing, researchers can screen through a thousand genes and identify the most significant to nerve injury. Similarly, bioinformatics platforms can incorporate microRNA<sup>9,27,28</sup> (miRNA) information, e.g., hsa-miR-8485, and predict their target genes, aiding in how post-transcriptional regulation is responsible for nerve dysfunction. Yet another strong connection is in the construction of biological networks.<sup>31,34</sup> Cytoscape is one software that allows scientists to visualize how genes, proteins, and pathways interact within the context of nerve damage. Instead of looking at individual molecules in silos, computational biology offers a systems-level snapshot shedding light on how dysregulated components interact to produce the resulting disease phenotype. To illustrate, if there are a few upregulated genes that fall into a single signaling pathway for oxidative stress or apoptosis, the implication is that pathway as a potential cause of nerve degeneration. In the same vein, protein-protein interaction (PPI) networks can identify hub genes or central regulators as potential diagnostic biomarkers or drug targets. In addition, computational biology assists in avoiding one of the largest challenges with nerve damage: narrow diagnosis.



**Figure 2:** AI Applications in nerve damage, where AI-enabled precision oncology streamlines diagnosis, prognosis, and treatment by allowing molecularly tailored therapies for each patient

The traditional clinical approaches are highly reliant on symptom observation and invasive testing, which generally prove to be inefficient in detecting early molecular changes. Computational examination of omics data from patients, however, can detect subtle gene expression changes, epigenetic changes, or metabolic changes long before symptoms are manifest. Combining these findings with machine learning models is even more enabling in terms of patient classification, predicting disease outcomes, and personalizing treatment strategies. It is particularly effective in multifactorial disorders where many of the factors including genetic, environmental, and lifestyle interact to lead to nerve damage. In this way, computational biology not only supplies the means to reveal the molecular mechanism of nerve damage but also provides new directions for early diagnosis, specific therapy, and drug development. By leveraging bioinformatics, researchers can transform heterogeneous molecular information into effective information, allowing translation between laboratory and clinical applications.<sup>4</sup>

### COMPUTATIONAL APPROACHES FOR STUDYING NERVE DAMAGE

The nature of nerve damage necessitates the involvement of multidisciplinary strategies


beyond traditional laboratory practice. Computational biology provides a wide range of tools and techniques by which researchers can gather, manipulate, and interpret biological information at various levels. Such strategies range from genomics, transcriptomics, proteomics, and metabolomics to machine learning, artificial intelligence, and network biology. They collectively provide a comprehensive platform to comprehend the molecular mechanisms of nerve injury, to create biomarkers, and to engineer novel therapies and diagnostic approaches.

#### 1. Genomics and Transcriptomics

*Genomics and Transcriptomics* are the cornerstone in uncovering genetic and molecular signatures that form the basis of nerve injury. The advent of next-generation sequencing (NGS) tools, including whole-genome sequencing (WGS) and whole-exome sequencing (WES), has made it possible to identify genetic variants, mutations, and polymorphisms that predispose a person to nerve injury or influence the course of the disease. Concurrently, RNA sequencing (RNA-Seq) allows high-throughput analysis of the transcriptome, which takes a snapshot of all active form genes expressed in uninjured and injured nerve tissue. Differential analysis of gene expression, carried out by computational

software like DESeq2<sup>22</sup> or edgeR,<sup>23</sup> points out which genes are upregulated or downregulated due to nerve injury. Moreover, microRNAs<sup>9,10,11</sup> (miRNAs), including hsa-miR-8485, have become vital post-transcriptional regulators in neurodegenerative diseases. Computational

miRNA prediction software, such as miRDB or TargetScan, is used to identify their target genes, thereby shedding light on regulatory mechanisms involved in the modulation of inflammation, apoptosis, and axonal regeneration.<sup>26,30</sup>



**Figure 3:** Computational approaches for studying nerve damage, integrating genomic, transcriptomic, and proteomic data with bioinformatics tools to identify biomarkers and therapeutic targets, these methods enable pathway analysis, network modeling, and prediction of potential treatments

## 2. Proteomics and Metabolomics

*Proteomics and Metabolomics* offer a significant level of insight through the analysis of proteins and metabolites that vary following nerve injury. Proteomics methods, aided by mass spectrometry and bioinformatics pipelines, facilitate the detection of protein biomarkers, their quantity, and post-translational modifications. Likewise, metabolomics analyzes small molecules and metabolite intermediates, which show physiological variation following nerve injury. Computational power allows for these datasets to be interpreted by pathway enrichment analysis, leveraging resources such as KEGG (Kyoto Encyclopedia of Genes and Genomes), Reactome, or g:Profiler. By mapping dysregulated genes, proteins, or metabolites onto biological pathways, researchers can ascertain which processes, such as oxidative stress, mitochondrial pathology, or inflammatory signaling are most affected during nerve injury. This systems-level view provides root-level insight into mechanisms of disease and therapeutic targets.<sup>13,14,25,26</sup>

## 3. Machine learning and Artificial Intelligence

Machine learning and artificial intelligence (AI) have revolutionized the interpretation of intricate biological data sets through predictive modeling<sup>32</sup> and biomarker discovery. Supervised machine learning methods, like support vector machines (SVMs) or random forests, can classify patient samples into nerve-injured and healthy classes using multi-omics data. Unsupervised learning approaches, including clustering and dimension reduction, reveal latent patterns in data that classify subtypes of nerve damage. Even more advanced deep learning models such as neural networks can integrate genomic, transcriptomic, proteomic, and clinical information to build models for predicting disease outcome or treatment response. Such computational programs allow for the detection of diagnostic biomarkers as well as precision medicine strategies, where drugs are tailored to a person's molecular phenotype.

## 4. Databases and Bioinformatics

*Databases and Bioinformatics Tools* are the preferred tool for nerve damage research

because they provide quality-filtered biological data and analysis workflows. KEGG<sup>15</sup> and Reactome<sup>16</sup> support pathway analysis, while g:Profiler<sup>17</sup> supports functional enrichment experiments by correlating gene sets with Gene Ontology (GO) terms, pathways, and disease associations. DisGeNET<sup>18</sup> has valuable gene-disease association information, while DGIdb<sup>19</sup> has drug-gene interaction information, which can help to identify potential therapeutic agents for nerve damage. Software packages like the STRING<sup>20</sup> and Cytoscape<sup>21</sup> tool packages are commonly used for visualizing and querying biological networks, in which functional protein-protein and gene-gene relationships are emphasized. Together, these tools speed up the process of converting raw biological data into useful clinical information.

## 5. Network Biology

Another potent tool for disentangling the multifunctional interactions giving rise to nerve injury is *Network Biology*. Rather than focusing on the behavior of individual molecules, network biology addresses the interactions among genes, proteins, and regulatory RNAs. Gene-gene networks, built from transcriptomic data, expose co-expression motifs indicating concurrent biological processes. Protein-protein interaction (PPI) networks identify central regulators or hub proteins that may be accountable for vital functions in disease processes. Similarly, miRNA-miRNA and miRNA-gene networks interpret regulatory networks that modify gene expression in brain tissues injured. These networks enable scientists to identify pivotal nodes or routes whose perturbation could be driving degeneration of the nerves, and as such are potential candidates for both diagnosis and therapy. Together, these computational strategies offer a universal framework for exploring the molecular intricacy of nerve injury. Genomics and transcriptomics reveal genetic predispositions and gene expression changes; proteomics and metabolomics disclose the functional implications at protein and metabolic levels; AI and machine learning allow prediction of biomarkers and patient stratification; databases and tools offer curated biological context; and network biology brings these layers together into systems-level models. Through the integration of these approaches, scientists can step toward

a greater, data-driven understanding of nerve damage. Significantly, such integrative computational techniques have huge potential for diagnosis, with the potential to identify molecular changes at early stages, distinguish between nerve damage subtypes, and inform individualized treatment plans. This transition from symptom-oriented to molecular-oriented diagnostics is a breakthrough in the clinical management of nerve disorders.

## CASE STUDIES AND APPLICATIONS


Computational biology has been instrumental in the discovery of molecular mechanisms behind nerve injury and neuropathic pain, which are commonly hard to interpret using traditional experimental methods alone. A good case in point is the identification of miR-146a-5p as an inflammatory signaling regulator in models of neuropathic pain. By applying computational miRNA-mRNA interaction prediction and subsequent experimental confirmation within a rat model of chronic constriction injury (CCI), scientists demonstrated that miR-146a-5p<sup>12</sup> targets IRAK1 and TRAF6, two key mediators of the NF- $\kappa$ B inflammatory pathway. Systemic delivery of a mimic of miR-146a-5p greatly decreased mechanical allodynia and thermal hyperalgesia, illustrating the potential of computational analysis to identify therapeutic targets within complex signaling networks. In a similar vein, computational screening of ion channel-related genes and their regulatory networks identified that various miRNAs, including miR-30b, miR-7a, and the miR-17-92 cluster, regulate voltage-gated sodium and potassium channels, determinants of neuronal excitability. The data inform mechanistically how dysregulation at the non-coding RNA level can affect nerve sensitivity and pain perception. Large-scale bioinformatic analysis has also been used in clinical datasets. Transcriptomic profiling of SCI patients with and without neuropathic pain, for example, revealed more than a thousand DEGs. Network analysis integrated with miRNA target prediction pointed to miR-204-5p and miR-20b-5p as promising circulating biomarkers for the distinction between neuropathic and non-neuropathic conditions. These methods not only identify molecular drivers of nerve pathology but also set the foundation for the development of precision diagnostics. Besides

miRNAs, computational epigenetic studies have revealed the mechanism of chronic pain persistence. Integrative analyses revealed that histone modifications H3K9me2 and H3K27me3 silence potassium channel and opioid receptor genes in dorsal root ganglia. The silencing of genes through epigenetics increases neuronal excitability and attenuates analgesic response, thus explaining acute to chronic pain transition. These findings, obtained from the integration of high-throughput data with pathway enrichment and network analysis, highlight the utility of computational tools in uncovering likely explanations of nerve damage.<sup>36-39</sup>

### MULTI-OMICS INTEGRATION IN NEURODEGENERATION

Although single-omics studies yield important information, multifactorial neurodegenerative diseases like Alzheimer's disease (AD) and

Parkinson's disease (PD) are extremely complex and need multi-omics integration to elucidate their entire biological picture. Consequently, the methods have moved towards collating genomics, transcriptomics, epigenomics, proteomics, metabolomics, and lipidomics into a joined-up approach. A dramatic example is derived from research incorporating blood transcriptomes with GWAS and eQTL information in Parkinson's disease. Through computationally superimposing gene expression profiles<sup>35</sup> with genetic risk loci, scientists found approximately a thousand DEGs of which ten were highly linked to aging-related processes. In addition, genes like MAP3K5 and SIRT3 were reported as protective elements, whereas machine learning models constructed from these integrated datasets maintained high predictive performance towards PD diagnosis, highlighting the translational potential of multi-omics analysis.<sup>30</sup>



**Figure 4:** Principal Molecular Methods Involved with Neuronal Survival & Death in which Genetic factors, DDR, mitophagy dysfunction, inflammation, and their crosstalk tells whether neurons survive or degenerate

Meta-analyses of several neurodegenerative diseases have identified common molecular signatures. Integrating transcriptomic and proteomic data sets from Alzheimer's, Parkinson's, Huntington's disease, and ALS, computational analyses identified 139 genes uniformly dysregulated across conditions. Enriched pathways included stress responses,

apoptosis, extracellular matrix remodeling, and RNA metabolism suggesting that there are common mechanisms of neurodegeneration regardless of clinical disease distinctions. At the cell level, multi-omics dissection with iPSC-derived microglia has unraveled how genetic risk variants APOE4 and TREM2 contribute to AD risk. By means of RNA-

seq, ATAC-seq, ChIP-seq, and proteomic integrative analysis, scientists demonstrated that APOE overexpression impairs amyloid- $\beta$  clearance and amplifies microglial activation. These results illustrate how integration across several molecular levels can supply a systems-level insight into disease mechanisms. The research area has also been facilitated through the creation of sophisticated computational frameworks tailored to multi-omics data integration. For instance, supervised deep learning algorithms like SDGCCA and graph neural network methods like MOTGNN allow for the identification of phenotype-specific biomarker clusters from heterogeneous omics data. These tools not only harmonize multiple data sources but also give interpretable models that direct experimental validation as well as biomarker prioritization.

## CHALLENGES AND FUTURE DIRECTIONS

As much as studies have advanced using computational biology and integration of multi-omics, there have been some challenges that still hinder the application of these findings to clinical use.

### 1. Data Heterogeneity

Among the most significant challenges is the heterogeneity of data. Neurological disease, such as nerve injury and neurodegeneration, is characterized by large variability among patients, tissue, and stages of disease. For example, specimens can be derived from blood, cerebrospinal fluid, post-mortem brain, or peripheral nerve<sup>1</sup>, each reflecting only a part of the biological landscape. In addition, patients are frequently of different ages, sexes, comorbidities, and treatments, resulting in heterogeneous molecular profiles. This heterogeneity makes it challenging to define universally relevant biomarkers or therapeutic targets. Standardization of data generation, preprocessing, and quality control is still a key requirement to guarantee reproducibility and comparability of studies.

### 2. Requirement for Multi Integrative-Omics and Computational Strategies

Integrating the heterogeneous omics layers is another key challenge. Genomic, transcriptomic, epigenomic, proteomic, metabolomic, and microbiome<sup>24</sup> data each have important information to convey, but their

integration into one framework is not a simple task. Various omics technologies produce data at different scales, depths, and resolutions, and thus need specific computational pipelines for harmonization. Present strategies tend to concentrate on one or two layers of data, but neurological conditions are multi-factorial by nature and need strategies capable of capturing the interactions between several molecular levels. Also, most studies use bulk tissue data, which obscures cell-type-specific information that is vital for the comprehension of disease mechanisms within heterogeneous tissues like the brain.

### 3. Future Directions: AI, Single-Cell Omics, and Network Models

In the future, several emerging approaches hold the key to overcoming these challenges. Artificial intelligence (AI) and machine learning (ML) are being used increasingly to detect complex, non-linear relationships in large-scale multi-omics data. Deep learning algorithms, graph neural networks, and interpretable ML methods can reveal latent associations among genes, proteins, metabolites, and clinical features and thereby help predict disease progression and treatment response.

Another revolutionary path includes the application of single-cell and spatial omics. Single-cell technologies, as opposed to bulk methods, offer a resolution-rich snapshot of cellular heterogeneity within the nervous system, allowing the detection of rare cell subtypes or cell populations responsible for disease. Single-cell transcriptomics and epigenomics, for instance, can uncover how neuronal or glial cell<sup>6</sup> populations cause neuroinflammation or neurodegeneration, while spatial omics traces these changes in real-time within the architecture of the brain. Lastly, developments in network biology and systems modeling<sup>32</sup> are crucial for overcoming descriptive studies to mechanistic understanding. Integrated network models that define gene-gene, protein-protein, and miRNA-mRNA interactions will enable scientists to identify crucial regulatory nodes and feedback loops that maintain pathological states. Dynamic and multilayered networks can also model disease progression and forecast the impact of therapeutic intervention, thus becoming valuable tools for translational neuroscience.<sup>29,33</sup>

## CONCLUSION

Computational biology has become a robust paradigm for deconstructing the complexity of nervous system disease, from acute nerve trauma to chronic neuropathies and progressive neurodegenerative disorders. Through the integration of genomics, transcriptomics<sup>30</sup>, epigenomics, proteomics, metabolomics, and network biology, computational approaches enable scientists to transcend reductionist paradigms and capture instead the multifactorial character of these diseases. In the case of nerve damage in particular, bioinformatics pipelines have played a key role in defining dysregulated pathways, miRNA biomarkers, and epigenetic regulators that account for why some people develop chronic neuropathic pain whereas others recover. These findings not only enhance our understanding of disease mechanisms but also offer candidate biomarkers for early detection and therapeutic treatment.<sup>6</sup>

Notably, computational methods are especially useful in research on rare or poorly explored neuropathies, where small patient samples and limited experimental resources are a concern. Utilizing publicly available datasets, predictive modeling, and cross-disease comparison, researchers can discover shared molecular signatures among related diseases, hence extrapolating information from well-studied conditions to rare conditions. This creates new possibilities for diagnosis and treatment even in the absence of standard clinical or experimental information.

In addition to discovery, computational biology<sup>40</sup> has significant implications for personalized medicine. Through the incorporation of multi-omics data and complemented by clinical, imaging, and patient-specific data, it is now possible to construct individualized disease profiles that forecast progression, drug response, and treatment resistance. For instance, machine learning models developed from omics data can classify patients into molecular subtypes, thus allowing for the selection of targeted therapies specific to their distinct molecular landscape. In the same way, single-cell and spatial omics integrated with network modeling<sup>32</sup> are starting to deliver cell-type specific therapeutic targets amenable for precision interventions in neuropathic pain<sup>7</sup> as well as neurodegeneration. In summary, computational biology is not only

revolutionizing our concept of nerve injury and neurodegeneration but also setting the stage for precision diagnoses and personalized treatments. Through the solution of existing hurdles in data heterogeneity and fusion and embracing cutting-edge computational paradigms, the discipline has the potential to revolutionize clinical management of neuropathies from unusual inherited diseases to common age-related neurodegenerative conditions ultimately leading to improved outcome and quality of life for patients.

## REFERENCES

1. Campbell, W. W., & Meyer, K. (2006). Peripheral neuropathy: diagnosis and management. *The Lancet Neurology*, 5(6), 455-464.
2. Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012). Diabetic neuropathy: clinical manifestations and current treatments. *The Lancet Neurology*, 11(6), 521-534.
3. van den Berg, L. H., & Kiernan, M. C. (2011). Guillain-Barré syndrome and other immune-mediated neuropathies. *The Lancet Neurology*, 10(9), 757-767.
4. Harding, A. E. (1993). The clinical features and classification of inherited neuropathies. *Journal of Neurology, Neurosurgery & Psychiatry*, 56(2), 121-128.
5. Coleman, M. (2005). Axon degeneration mechanisms: commonality amid diversity. *Nature Reviews Neuroscience*, 6(11), 889-898.
6. Scholz, J., & Woolf, C. J. (2007). The neuropathic pain triad: neurons, immune cells and glia. *Nature Neuroscience*, 10(11), 1361-1368.
7. Costigan, M., Scholz, J., & Woolf, C. J. (2009). Neuropathic pain: a maladaptive response of the nervous system to damage. *Annual Review of Neuroscience*, 32, 1-32.
8. Denk, F., McMahon, S. B., & Tracey, I. (2014). Pain vulnerability: a neurobiological perspective. *Nature Neuroscience*, 17(2), 192-200.
9. Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. *Cell*, 136(2), 215-233.
10. Krol, J., Loedige, I., & Filipowicz, W. (2010). The widespread regulation of microRNA biogenesis, function and decay. *Nature Reviews Genetics*, 11(9), 597-610.
11. Yu, B., et al. (2015). MicroRNA-mediated regulation in neuropathic pain. *Nature Reviews Neurology*, 11(5), 323-334.

12. Iyer, A., & Zare, H. (2014). miR-146a in inflammation and neuropathic pain: mechanistic insights and therapeutic potential. *Journal of Neuroinflammation*, 11, 184.
13. Mann, M. (2006). Functional and quantitative proteomics using SILAC. *Nature Reviews Molecular Cell Biology*, 7(12), 952–958.
14. Nicholson, J. K., Lindon, J. C., & Holmes, E. (1999). 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. *Xenobiotica*, 29(11), 1181–1189.
15. Kanehisa, M., & Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Research*, 28(1), 27–30.
16. Fabregat, A., et al. (2018). The Reactome pathway Knowledgebase. *Nucleic Acids Research*, 46(D1), D649–D655.
17. Raudvere, U., et al. (2019). g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Research*, 47(W1), W191–W198.
18. Piñero, J., et al. (2017). DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. *Nucleic Acids Research*, 45(D1), D833–D839.
19. Cotto, K. C., et al. (2018). DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. *Nucleic Acids Research*, 46(D1), D1068–D1073.
20. Szklarczyk, D., et al. (2019). STRING v11: protein-protein association networks with increased coverage. *Nucleic Acids Research*, 47(D1), D607–D613.
21. Shannon, P., et al. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Research*, 13(11), 2498–2504.
22. Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. *Genome Biology*, 15(12), 550.
23. Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*, 26(1), 139–140.
24. Bolyen, E., et al. (2019). Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nature Biotechnology*, 37(8), 852–857.
25. Douglas, G. M., et al. (2020). PICRUSt2 for prediction of metagenome functions. *Nature Biotechnology*, 38(6), 685–688.
26. Franzosa, E. A., et al. (2018). Species-level functional profiling of metagenomes and metatranscriptomes. *Nature Methods*, 15(11), 962–968.
27. Agarwal, V., Bell, G. W., Nam, J.-W., & Bartel, D. P. (2015). Predicting effective microRNA target sites in mammalian mRNAs. *eLife*, 4, e05005. (TargetScan algorithm paper)
28. Wang, X. (2008). miRDB: a microRNA target prediction and functional annotation database with a wiki interface. *RNA*, 14(6), 1012–1017.
29. Stuart, T., et al. (2019). Comprehensive integration of single-cell data. *Cell*, 177(7), 1888–1902.e21. (Seurat v3 integration)
30. Ståhl, P. L., et al. (2016). Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. *Science*, 353(6294), 78–82.
31. Kleftogiannis, D., et al. (2020). Graph neural networks and their applications in protein structural biology. *Briefings in Bioinformatics*, 22(6), bbz145.
32. Zitnik, M., Agrawal, M., & Leskovec, J. (2018). Modeling polypharmacy side effects with graph convolutional networks. *Bioinformatics*, 34(13), i457–i466.
33. Hwang, B., Lee, J. H., & Bang, D. (2018). Single-cell RNA sequencing technologies and bioinformatics pipelines. *Experimental & Molecular Medicine*, 50(8), 96.
34. Liao, Y., Smyth, G. K., & Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics*, 30(7), 923–930.
35. Subramanian, A., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences (PNAS)*, 102(43), 15545–15550.
36. Iyer, A., Zurolo, E., Prabowo, A., Fluiter, K., Splet, W. G., van Rijen, P. C., ... Aronica, E. (2012). MicroRNA-146a: A key regulator of astrocyte-mediated inflammatory response. *PLoS ONE*, 7(9), e44789.
37. Li, K., Zhong, Y., & Wang, Z. (2019). MicroRNAs and ion channels in neuropathic pain. *International Journal of Molecular Sciences*, 20(19), 4937.

38. Li, H., Wang, D., Sun, H., Mu, X., & Chen, L. (2020). Transcriptomic analysis identifies potential biomarkers in patients with spinal cord injury and neuropathic pain. *Journal of Neuroinflammation*, 17, 102.
39. Denk, F., McMahon, S. B., & Tracey, I. (2014). Pain vulnerability: A neurobiological perspective. *Nature Neuroscience*, 17(2), 192-200.
40. Luscombe, N. M., Greenbaum, D., & Gerstein, M. (2001). What is bioinformatics? A proposed definition and overview of the field. *Methods of Information in Medicine*, 40(4), 346-358.